Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer

被引:44
作者
Duong, Cuong P.
Demitriou, Helen
Weih, LeAnn
Thompson, Anne
Williams, David
Thomas, Robert J. S.
Hicks, Rodney J.
机构
[1] Peter MacCallum Canc Ctr, Ctr Mol Imaging, Melbourne, Vic 8006, Australia
[2] Peter MacCallum Canc Ctr, Div Surg Oncol, Melbourne, Vic 8006, Australia
[3] Peter MacCallum Canc Ctr, Ctr Stat, Melbourne, Vic 8006, Australia
基金
英国医学研究理事会;
关键词
FDG-PET; oesophageal cancer; staging; impact; prognosis;
D O I
10.1007/s00259-005-0028-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To evaluate the clinical impact of FDG-PET in staging oesophageal cancer and whether this information improves prognostic stratification. Methods: Impact was based on comparison of a prospectively recorded pre-PET plan with post-PET treatment in 68 consecutive patients undergoing primary staging. Survival was analysed using the Kaplan-Meier product limit method and the Cox proportional hazards regression model. Results: FDG-PET findings impacted on the management of 27/68 patients (40%): in 12 therapy was changed from curative to palliative and in three from palliative to curative, while in 12 other patients there was a change in the treatment modality or delivery but not in the treatment intent. The median survival was 21 months, with post-PET stage and treatment intent both strongly associated with survival (p < 0.001). Conventional stage was not able to clearly stratify this population. Conclusion: The use of FDG-PET for primary staging of oesophageal cancer changed the clinical management of more than one-third of patients and provided superior prognostic stratification compared with conventional investigations.
引用
收藏
页码:759 / 769
页数:11
相关论文
共 45 条
[1]   The additional value of PET/CT over PET in FDG imaging of oesophageal cancer [J].
Bar-Shalom, R ;
Guralnik, L ;
Tsalic, M ;
Leiderman, M ;
Frenkel, A ;
Gaitini, D ;
Ben-Nun, A ;
Keidar, Z ;
Israel, O .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (08) :918-924
[2]   Improvement in staging of esophageal cancer with the addition of positron emission tomography [J].
Block, MI ;
Patterson, GA ;
Sundaresan, RS ;
Bailey, MS ;
Flanagan, FL ;
Dehdashti, F ;
Siegel, BA ;
Cooper, JD .
ANNALS OF THORACIC SURGERY, 1997, 64 (03) :770-776
[3]  
Blot WJ, 1999, SEMIN ONCOL, V26, P2
[4]   Impact of positron emission tomography on the management of patients with small-cell lung cancer - Preliminary experience [J].
Blum, R ;
MacManus, MP ;
Rischin, D ;
Michael, M ;
Ball, D ;
Hicks, RJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (02) :164-171
[5]   Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma [J].
Blum, RH ;
Seymour, JF ;
Wirth, A ;
MacManus, M ;
Hicks, RJ .
CLINICAL LYMPHOMA, 2003, 4 (01) :43-49
[6]  
Buenaventura P, 2000, Chest Surg Clin N Am, V10, P487
[7]  
Choi JY, 2004, J NUCL MED, V45, P1843
[8]  
Choi JY, 2000, J NUCL MED, V41, P808
[9]  
Duhaylongsod FG, 1997, ANN THORAC SURG, V64, P776
[10]   Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma [J].
Flamen, P ;
Lerut, A ;
Van Cutsem, E ;
De Wever, W ;
Peeters, M ;
Stroobants, S ;
Dupont, P ;
Bormans, G ;
Hiele, M ;
De Leyn, P ;
Van Raemdonck, D ;
Coosemans, W ;
Ectors, N ;
Haustermans, K ;
Mortelmans, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3202-3210